

# US Bispecific Antibodies Market & Clinical Pipeline Insight 2028

<https://marketpublishers.com/r/U9B05E7C2A09EN.html>

Date: August 2023

Pages: 580

Price: US\$ 4,200.00 (Single User License)

ID: U9B05E7C2A09EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

US Bispecific Antibodies Market & Clinical Pipeline Insight 2028 Report Highlights:

US Bispecific Antibodies Market Opportunity: > USD 15 Billion By 2028

FDA Approved Bispecific Antibodies: 11 Antibodies

Approved Bispecific Antibodies Dosage, Price & Sales Insight

Bispecific Antibodies Reimbursement Medicare, Medicaid & Drug Specific Policy

Comprehensive Clinical Insight On Bispecific Antibodies In Pipeline: > 300 Antibodies

US Bispecific Antibodies Clinical Pipeline Insight By Company, Indication & Phase

Comprehensive Clinical Insight On Approved Bispecific Antibodies

In the realm of biopharmaceuticals, bispecific antibodies have emerged as a revolutionary class of therapies, opening new frontiers in precision medicine. These innovative molecules are designed to simultaneously target two distinct antigens, unlocking the potential for transformative treatment approaches across various diseases. From oncology to autoimmune disorders, infectious diseases to

neurodegenerative conditions, bispecific antibodies offer a clinical perspective that is reshaping patient care and inspiring new possibilities for precision therapies. In respect to this, the US market has emerged as frontrunner in commercializing this transformative therapeutic modality, and is now leading the development of bispecific antibodies, with several US based drugs makers having innovative bispecific antibodies candidates under development.

One of the key clinical perspectives of bispecific antibodies is their precision targeting capabilities. By engaging two specific antigens simultaneously, bispecific antibodies can be tailored to address unique molecular signatures of diseases. This precision targeting allows for more effective therapeutic interventions, minimizing off target effects on healthy tissues and reducing adverse events commonly associated with traditional treatments. Researchers in the US were the first to hypothesize the use of bispecific antibodies in cancer treatment, and pursuant research and clinical studies demonstrated bispecific antibodies to revolutionize the approach to cancer treatment. By precisely engaging immune cells to target cancer cells, these therapies unleash potent immune responses against tumors while sparing healthy tissues, leading to improved tumor control and better patient outcomes.

Clinical trials have demonstrated remarkable success in hematological malignancies, such as acute lymphoblastic leukemia (ALL) and multiple myeloma, as well as solid tumors like breast cancer and melanoma. The US bispecific antibodies market has witnessed the approval of several groundbreaking therapies that have extended survival rates, improved response rates, and provided new treatment options for patients with refractory or relapsed cancers. The US bispecific antibody market has also shown promise in addressing infectious diseases. Bispecific antibodies can be engineered to simultaneously neutralize pathogens and stimulate the immune system, boosting the body's ability to fight infections effectively.

US is also paving the way for innovative therapies in neurological disorders. Bispecific antibodies are being explored to target misfolded proteins implicated in neurodegenerative conditions like Alzheimer's and Parkinson's disease. By specifically targeting these pathological proteins and facilitating their clearance, bispecific antibodies offer a potential disease-modifying approach. The clinical impact of these therapies could potentially slow disease progression and improve the quality of life for patients living with these devastating neurological disorders.

From a clinical perspective, bispecific antibodies also hold promise in addressing treatment challenges posed by traditional therapies. For instance, drug resistance is a

major obstacle in cancer treatment. Bispecific antibodies, with their dual-targeting capabilities, can circumvent resistance mechanisms and offer new avenues for patients who have exhausted conventional therapies. Additionally, the ability of bispecific antibodies to penetrate specific tissues or cross the blood-brain barrier allows for more effective delivery of therapies to disease sites that were previously difficult to target. This opens up possibilities for addressing neurological disorders and other conditions with limited treatment options.

The US has been at the forefront of biopharmaceutical innovation, consistently driving advancements in the field of medicine. In recent years, the country's clinical development of bispecific antibodies has not only transformed patient care within its borders but has also had a profound impact on the global market. As the first country to approve several bispecific antibodies therapies, the US has set standard for global regulatory agencies. International regulators often align their evaluation processes with the FDA's standards, benefiting patients worldwide by expediting approvals and facilitating access to transformative treatments.

The influx of global investment further bolsters R&D efforts, creating a virtuous cycle of progress. This infusion of funds enables companies to expand clinical trials, explore new therapeutic applications, and develop a more diverse pipeline of bispecific antibodies with broad-reaching clinical implications. The US leadership in the clinical development of bispecific antibodies has sparked numerous collaborations and partnerships on an international scale. Research institutions, companies, and clinicians from around the world seek to collaborate with US based organizations to access expertise, technologies, and resources.

These collaborations foster knowledge-sharing and resource pooling, contributing to a collective effort in advancing the global understanding of bispecific antibodies. Such partnerships have resulted in joint clinical trials and the exploration of diverse therapeutic applications across different countries. As the US continues to lead in research, clinical trials, and regulatory approvals, the global market for bispecific antibodies expands, providing new hope for patients facing complex diseases worldwide. Through pioneering efforts, collaborations, and investments, the US has positioned itself as a driving force in the evolving landscape of precision medicine. The impacts of its clinical developments have the potential to revolutionize patient care on a global scale.

## Contents

### **1. US BISPECIFIC ANTIBODIES MARKET OUTLOOK**

- 1.1 US Commercially Approved Bispecific Antibodies
- 1.2 US Bispecific Antibodies Market Current Scenario
- 1.3 US Bispecific Antibodies Clinical Development & Commercial Collaborative Perspective
- 1.4 US Bispecific Antibodies Market Future Outlook

### **2. US BISPECIFIC ANTIBODIES MARKET TRENDS BY INDICATION**

- 2.1 Cancer
- 2.2 Ophthalmology
- 2.3 Autoimmune & Inflammatory Diseases
- 2.4 Blood Disorders

### **3. US BISPECIFIC ANTIBODIES REIMBURSEMENT SCENARIO**

- 3.1 Medicare
- 3.2 Medicaid
- 3.3 Private Insurers
- 3.4 Pharmaceutical Companies
- 3.5 Approved Bispecific Antibodies Reimbursement Policies

### **4. BLINCYTO: 1ST APPROVED BISPECIFIC ANTIBODY**

- 4.1 Overview & Patent Insight
- 4.2 Pricing & Dosage Analysis
- 4.3 Sales Analysis

### **5. HEMLIBRA: 2ND APPROVED BISPECIFIC ANTIBODY**

- 5.1 Overview
- 5.2 Dosage & Price Analysis
- 5.3 Sales Analysis

### **6. RYBREVANT: 3RD APPROVED BISPECIFIC ANTIBODY**

- 6.1 Overview
- 6.2 Dosage & Price Analysis
- 6.3 Sales Analysis

## **7. KIMMTRAK: 4TH APPROVED BISPECIFIC ANTIBODY**

- 7.1 Overview
- 7.2 Pricing & Dosage Insight
- 7.3 Sales Analysis

## **8. VABYSMO: 5TH APPROVED BISPECIFIC ANTIBODY**

- 8.1 Overview
- 8.2 Dosage & Price Analysis
- 8.3 Sales Analysis

## **9. LUNSUMIO: 6TH APPROVED BISPECIFIC ANTIBODY**

- 9.1 Overview & Patent Insight
- 9.2 Dosage & Price Analysis
- 9.3 Sales Analysis

## **10. TECVAYLI: 7TH APPROVED BISPECIFIC ANTIBODY**

- 10.1 Overview & Patent Insight
- 10.2 Pricing & Dosage Insight

## **11. COLUMVI: 8TH APPROVED BISPECIFIC ANTIBODY**

- 11.1 Overview & Patent Insight
- 11.2 Pricing & Dosage Insight

## **12. EPKINLY: 9TH APPROVED BISPECIFIC ANTIBODY**

- 12.1 Overview & Patent Insight
- 12.2 Pricing & Dosage Insight

## **13. TALVEY: 10TH APPROVED BISPECIFIC ANTIBODY**

13.1 Overview

13.2 Pricing & Dosage Insight

## **14. ELREXFIO: 11TH APPROVED BISPECIFIC ANTIBODY**

14.1 Overview

14.2 Pricing & Dosage Insight

## **15. US BISPECIFIC ANTIBODIES CLINICAL PIPELINE OVERVIEW**

15.1 By Phase

15.2 By Biomarker

15.3 By Company

15.4 By Indication

15.5 Patient Segment

## **16. US BISPECIFIC ANTIBODIES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

16.1 Research

16.2 Preclinical

16.3 Phase-I

16.4 Phase-I/II

16.5 Phase-II

16.6 Phase-II/III

16.7 Phase-III

## **17. US MARKETED BISPECIFIC ANTIBODIES CLINICAL INSIGHT BY COMPANY & INDICATION**

## **18. COMPETITIVE LANDSCAPE**

18.1 AbbVie

18.2 ABL Bio

18.3 Abpro Therapeutics

18.4 Abzyme Therapeutics

18.5 Affimed Therapeutics

18.6 Agenus

18.7 Amberstone Biosciences

- 18.8 Amgen
- 18.9 Antibody Therapeutics
- 18.10 Aptevo Therapeutics
- 18.11 Astellas Pharma
- 18.12 AstraZeneca
- 18.13 BioAtla
- 18.14 Boehringer Ingelheim
- 18.15 Bristol-Myers Squibb
- 18.16 Chugai Pharmaceutical
- 18.17 CytomX Therapeutics
- 18.18 Cytovia Therapeutics
- 18.19 Dren Bio
- 18.20 Elpis Biopharmaceuticals
- 18.21 EpimAb Biotherapeutics
- 18.22 Genentech
- 18.23 Genmab
- 18.24 GO Therapeutics
- 18.25 Harbour BioMed
- 18.26 IGM Biosciences
- 18.27 ImmunoPrecise Antibodies
- 18.28 Innovent Biologics
- 18.29 Integral Molecular
- 18.30 Invenra
- 18.31 Janssen Biotech
- 18.32 Kenjockey Biotechnology
- 18.33 L and L Biopharma
- 18.34 MacroGenics
- 18.35 Marengo Therapeutics
- 18.36 Memorial Sloan-Kettering Cancer Center
- 18.37 Merus
- 18.38 NovaRock Biotherapeutics
- 18.39 Pfizer
- 18.40 Phanes Therapeutics
- 18.41 QLSF Biotherapeutics
- 18.42 Regeneron Pharmaceuticals
- 18.43 Revitope
- 18.44 Roche
- 18.45 Surrozen
- 18.46 Talem Therapeutics

18.47 Virtuoso Therapeutics

18.48 Xencor

18.49 Zhejiang Shimai Pharmaceutical

18.50 Zymeworks



## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Blincyto - Mechanism of Action
- Figure 1-2: Hemlibra - Mechanism of Action
- Figure 1-3: Rybrevant - Mechanism of Action
- Figure 1-4: US FDA – Approved Bispecific Antibodies
- Figure 1-5: US – Bispecific Antibodies Market Annual Sales (US\$ Million), 2014-2023\*
- Figure 1-6: US – Bispecific Antibodies Market Annual Sales Value By Drugs, 2022
- Figure 1-7: US – Bispecific Antibodies Market Quarterly Sales Value, 2022
- Figure 1-8: US – Bispecific Antibodies Market Sales Value By Drugs, 2023\*
- Figure 1-9: US - Bispecific Antibodies Market Opportunity Assessment (US\$ Billion),

### 2023 – 2028

- Figure 2-1: BCDI-XII Phase 1 Study – Initiation & Completion Years
- Figure 3-1: Blincyto - Total Treatment Cost & Reimbursement Cost
- Figure 3-2: Blincyto – In Pocket & Out of Pocket Cost of Treatment
- Figure 3-3: Hemlibra - Total Treatment Cost & Reimbursement Cost
- Figure 3-4: Hemlibra – In Pocket & Out of Pocket Cost of Treatment
- Figure 3-5: Hemlibra - Maximum Coverage by NCDHHS (US\$), 2023
- Figure 3-6: Rybrevant - Maximum Coverage by NCDHHS (US\$), 2023
- Figure 3-7: Rybrevant - Maximum Coverage by Private Insurance Coverage (US\$),

### 2021

- Figure 3-8: Kimmtrak - Maximum Coverage by NCDHHS (US\$), 2023
- Figure 3-9: Vabysmo - Total Treatment Cost & Reimbursement Cost
- Figure 3-10: Vabysmo – In Pocket & Out of Pocket Cost of Treatment
- Figure 3-11: Lunsumio - Maximum Coverage by NCDHHS (US\$), 2023
- Figure 4-1: Blincyto – Approval Years By Country
- Figure 4-2: Blincyto – Patent Filing & Expiration Years
- Figure 4-3: Blincyto Treatment Regimen Cycles (Weeks), August'2023
- Figure 4-4: Blincyto – Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days), August'2023
- Figure 4-5: Blincyto - Cost of Single Cycle & Treatment Course for the Treatment of MRD-positive B-cell Precursor ALL, August'2023

- Figure 4-6: Blincyto – Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, August'2023
- Figure 4-7: Blincyto – Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), August'2023
- Figure 4-8: Blincyto - Cost of Single Cycle & Treatment Course for Treatment for Relapsed B-Cell Precursor ALL, August'2023
- Figure 4-9: US – Blincyto Sales Value (US\$ Million), 2014-2023\*
- Figure 4-10: US – Blincyto Quarterly Sales (US\$ Million), 2023
- Figure 4-11: US – Blincyto Quarterly Sales (US\$ Million), 2022
- Figure 5-1: Hemlibra – Approval Years
- Figure 5-2: Hemlibra – Cost for Single Unit of 30 mg/mL & 150 mg/mL Subcutaneous Injection (US\$), August'2023
- Figure 5-3: Hemlibra – Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/kg/Week), August'2023
- Figure 5-4: US – Hemlibra Sales Value (US\$ Million), 2018-2023\*
- Figure 5-5: US – Hemlibra Quarterly Sales (US\$ Million), 2023
- Figure 5-6: US – Hemlibra Quarterly Sales (US\$ Million), 2022
- Figure 6-1: Rybrevant – Price for 7 ml Supply & Price per Unit of 50 mg/ml Intravenous Solution (US\$), August'2023
- Figure 6-2: Rybrevant – Recommended Dose Per Cycle by Body Weight (mg), August'2023
- Figure 6-3: Rybrevant – Dose Reduction in Patients with Weight Less Than 80 kg (mg) , August'2023
- Figure 6-4: Rybrevant – Dose Reduction in Patients with Weight More Than 80 Kg (mg) , August'2023
- Figure 7-1: Kimmtrak – Approval Years
- Figure 7-2: Kimmtrak – Cost Per Unit & Per Vial (US\$), August'2023
- Figure 7-3: US – Annual Kimmtrak Sales (US\$ Million), 2022 & 2023
- Figure 7-4: US – Quarterly Kimmtrak Sales (US\$ Million), 2023
- Figure 7-5: US – Quarterly Kimmtrak Sales (US\$ Million), 2022
- Figure 8-1: Vabysmo – Approval Years
- Figure 8-2: Vabysmo – Price for 0.05 ml Supply & Price per Unit of 6mg/0.05ml Intravitreal Solution (US\$), August'2023
- Figure 8-3: US – Vabsymo Sales Value (US\$ Million), 2022-2023\*
- Figure 8-4: US – Vabysmo Quarterly sales (US\$ Million), 2023
- Figure 8-5: US – Quarterly Vabsymo Sales (US\$ Million), 2022
- Figure 9-1: Lunsumio – Approval Years
- Figure 9-2: Lunsumio – Price & Price per unit for Supply of 30 mg/30 ml Intravenous Solution (US\$), August'2023

Figure 9-3: US – Lunsumio Sales Value, 2023

Figure 9-4: US – Lunsumio Quarterly Sales (US\$ Million), 2023

Figure 10-1: Tecvayli – Approval Years

Figure 10-2: Tecvayli – Patent Acceptance & Expiration Years

Figure 10-3: US – Cost of 10 mg/ ml Tecvayli Vial (US\$), August'2023

Figure 10-4: US - Cost of 90 mg/mL Tecvayli Vial (US\$), August'2023

Figure 10-5: EU - Cost of 10 mg/ml Tecvayli Vial (US\$), August'2023

Figure 10-6: EU - Cost of 153 mg/1.7 mL Tecvayli Vial (US\$), August'2023

Figure 12-1: Epkinly – Price per Unit for 4mg & 48 mg Subcutaneous Solution of 0.8mL, August'2023

Figure 15-1: US - Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2023

Figure 15-2: US - Bispecific Antibodies in Clinical Pipeline by Biomarker (Numbers),

## **2023**

Figure 15-3: US - Bispecific Antibodies in Clinical Pipeline by Company (Numbers),

## **2023**

Figure 15-4: US - Bispecific Antibodies in Clinical Pipeline by Indication (Numbers),

## **2023**

Figure 15-5: Global - Bispecific Antibodies in Clinical Pipeline by Patient Segment (Numbers), 2023

## List Of Tables

### LIST OF TABLES

Table 1-1: US FDA - Approved Bispecific Antibodies

Table 4-1: Blincyto – Active Patents

Table 4-2: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL, August'2023

Table 4-3: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL, August'2023

Table 4-4: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL, August'2023

Table 6-1: Rybrevant – Premedication, August'2023

Table 6-2: Rybrevant - Dose Reductions for Adverse Reactions, August'2023

Table 6-3: Rybrevant - Recommended Dosage Modifications for Adverse Reactions, August'2023

Table 7-1: Kimmtrak - Recommended Dosage for Treatment of Unresectable or Metastatic Uveal Melanoma, August'2023

Table 7-2: Kimmtrak - Dose Modifications for Adverse Reactions, August'2023

Table 9-1: Lunsumio – Treatment Cycles, August'2023

Table 9-2: Lunsumio - Premedications, August'2023

Table 9-3: Lunsumio - Recommendations for Management of Cytokine Release Syndrome, August'2023

Table 10-1: Tecvayli - Dosing Schedule, August'2023

Table 10-2: Tecvayli - Recommended Dosage Modifications for Adverse Reactions, August'2023

Table 11-1: Columvi Dosing Schedule (21-Day Treatment Cycles), August'2023

Table 11-2: Recommended Dosage for Restarting Columvi After Dose Delay, August'2023

Table 12-1: Recommended Epkinly Dosage Schedule, August'2023

Table 12-2: Recommendations for Restarting Therapy with Epkinly after Dose Delay,

Table 13 1: Talvey - Weekly Dosing Schedule

Table 13 2: Talvey - Biweekly (Every 2 Weeks) Dosing Schedule

Table 13 3: Talvey - Recommendations for Management of CRS

Table 14 1: Elrexfio - Dosing Schedule

Table 14 2: Elrexfio - Recommendations for Management of CRS

## I would like to order

Product name: US Bispecific Antibodies Market & Clinical Pipeline Insight 2028

Product link: <https://marketpublishers.com/r/U9B05E7C2A09EN.html>

Price: US\$ 4,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U9B05E7C2A09EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970